NCT02233543View on ClinicalTrials.gov

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 26, 2016

Study Completion Date

June 26, 2016

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

QVA149

Delivered once daily via single-dose dry powder inhaler

DRUG

QVA149 Placebo

Placebo delivered once daily via single-dose dry powder inhaler

Trial Locations (5)

2650

Novartis Investigative Site, Hvidovre

8000 C

Novartis Investigative Site, Aarhus

-N5021

Novartis Investigative Site, Bergen

413 45

Novartis Investigative Site, Gothenburg

SE-751 85

Novartis Investigative Site, Uppsala

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY